Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
Provides information from the cutting edge of protease inhibitor developments
Chapters written by outstanding experts in the fields
The 8th volume in the Proteases in Biology and Disease series focuses on the role of proteases in virus function and their potential as anti-viral targets. Viral infections are still difficult to threat and some remained life-threatening diseases in spite of antiviral drug research over decades. Proteases are still regarded as an Achilles’ heel of the pathogens and, thus, protease inhibitors may help to handle the known and the emerging viral threads. The book discusses viral proteases of the most important pathogenic viruses, responsible for severe diseases: AIDS, SARS, Hepatitis, Cytomegalovirus, T-cell lymphotropic virus, Picornavirus. This book focuses specifically on the viral proteases, crucial prerequisites for viral entry into cells and viral replication. Viral proteases represent an important pharmaceutical target. The current stage of protease inhibitor development and therapy are summarised and discussed by experts in the field. This volume represents a timely and valuable continuation of the Proteases in Biology and Disease series. The reader will learn the potential for proteases as targets for effective anti-virals. This book will be a valuable source of information on viral proteases and provoke further research in this important field.
Preface. Contributors. 1.Study of Inhibitors Against SARS Coronavirus by Computational Approaches; Kuo-Chen Chou, Dong-Qing Wei, Qi-Shi Du, Suzanne Sirois, Hong-Bin Shen and Wei-Zhu Zhon. 2. HIV-1 Protease and AIDS Therapy; Irene T. Weber, Ying Zhang, and Jozsef Tozser. 3. Hepatitis C Virus; Philip Tedbury and Mark Harris. 4. Antiviral Activity of Proteasome Inhibitors/Cytomegalovirus; Marion Kaspari and Elke Bogner. 5. Rational Drug Design of HTLV-I Protease Inhibitors; Jeffrey-Tri Nguyen and Yoshiaki Kiso. 6. Picornaviruses; David Neubauer, Jutta Steinberger, and Tim Skern. Index.